Biophytis (EPA:ALBPS)

REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 6 months 24 days ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
BRIEF

published on 09/11/2025 at 07:05, 6 months 28 days ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 6 months 28 days ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 7 months 6 days ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 7 months 6 days ago

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Biophytis obtains EMA authorization to launch Phase 2 clinical trial of BIO101 in obesity, marking a significant regulatory milestone in Europe

Biophytis Phase 2 Clinical Trial Obesity EMA Authorization Regulatory Milestone
BRIEF

published on 09/01/2025 at 07:05, 7 months 8 days ago

Biophytis Announces Phase 2 Obesity Trial with BIO101

Biophytis Phase 2 Trial BIO101 Obesity Muscle Wasting
REGULATED PRESS RELEASE

published on 09/01/2025 at 07:00, 7 months 8 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis reveals Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting in obese patients. Expanding therapeutic horizons and commercial prospects

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
PRESS RELEASE

published on 09/01/2025 at 06:59, 7 months 8 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis unveils Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting associated with obesity. The new program broadens potential and value-creation opportunities globally

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
BRIEF

published on 08/28/2025 at 07:05, 7 months 12 days ago

Biophytis Gains Regulatory Approval for Phase 3 Sarcopenia Trial

Biophytis Regulatory Approval Clinical Trial Sarcopenia Phase 3
REGULATED PRESS RELEASE

published on 08/28/2025 at 07:00, 7 months 12 days ago

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, marking a significant milestone in developing therapies for muscle loss in aging individuals

Biophytis Sarcopenia Phase 3 EMA Belgian Regulatory Approval

Published on 04/09/2026 at 23:05, 10 minutes ago

Caldwell Reports Second Quarter Results
Published on 04/09/2026 at 23:00, 15 minutes ago

Apex Critical Metals to Attend Critical Materials Conference: Aerospace & Defence in Washington, DC
Published on 04/09/2026 at 19:15, 4 hours ago

Murchison Minerals Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 04/09/2026 at 16:00, 7 hours 15 minutes ago

Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 8 hours 35 minutes ago

Silver X Delivers Production Growth During the First Quarter of 2026

View all ACCESSWIRE

Published on 04/09/2026 at 22:00, 1 hour 14 minutes ago

Invitation - First Quarter 2026 Trading Update Conference Call
Published on 04/09/2026 at 21:01, 2 hours 13 minutes ago

GEVELOT S.A.: PRESS RELEASE CLOSING OF 2025 ACCOUNTS
Published on 04/09/2026 at 20:03, 3 hours 11 minutes ago

Annual General Meeting approves all proposals
Published on 04/09/2026 at 18:15, 4 hours 59 minutes ago

REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:59, 7 hours 15 minutes ago

Cairn Homes Plc: Holding(s) in Company

View all EQS

Published on 04/09/2026 at 18:35, 4 hours 40 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 17:35, 5 hours 40 minutes ago

SUEZ - FY 2025
Published on 04/09/2026 at 15:57, 7 hours 17 minutes ago

Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 16 hours 15 minutes ago

bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 5 hours ago

Publication of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News